By Ben GlickmanShares of Harpoon Therapeutics fell Wednesday after the company said AbbVie wouldn't exercise an exclusive license option on one of its treatments. The stock was down 7.3% to $6.06 after-hours, after falling 4% at Wednesday's close. The South San Francisco, Calif.-based immuno-oncology company said that under an agreement set to expire Oct. 12, AbbVie had an exclusive license option on HPN217, a program made by Harpoon which targets B cell maturation antigen. Harpoon plans to complete the current Phase 1 trial to continue developing the drug. Write to Ben Glickman at ben.glickman@wsj.com(END) Dow Jones NewswiresSeptember 13, 2023 16:57 ET (20:57 GMT)Copyright (c) 2023 Dow Jones & Company, Inc.

Source: Wall Street Journal September 14, 2023 09:07 UTC